Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ECT-001 by ExCellThera for Myelodysplastic Syndrome: Likelihood of Approval
ECT-001 is under clinical development by ExCellThera and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II...